MedTrace Logo

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

NCT01603082 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 343

Last updated 2015-12-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Ticagrelor

180 mg loading dose

DRUG

Clopidogrel

600 mg loading dose

Sponsors & Collaborators

Principal Investigators

  • Glenn F. Carlson, MD · AstraZeneca Pharmaceuticals, Wilmington, DE 19850-5437 USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01603082 on ClinicalTrials.gov